Abstracts Archive - Page 80 of 2425 - ACR Meeting Abstracts

Abstract Number: 0382 • ACR Convergence 2024
Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation
Ilaria Maccora¹, Mariia Pavlenko², Jackeline Rodriguez-Smith³, Amy Cassedy⁴, Mekibib Altaye⁵, hermine brunner⁶, Alexandra Duell⁵, Alexei Grom⁵, Theresa Hennard⁷, Virginia Miraldi Utz⁵, Najima Mwase⁵, Megan Quinlan-Waters⁵, grant schulert⁵, Alyssa Sproles⁸, Jessica Shantha⁹, Sunil K Srivastava¹⁰, Sherry Thornton⁸, Steven Yeh¹¹ and sheila Angeles-Han¹², ¹?PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Florence Italy, Firenze, Florence, Italy, ²Division of Rheumatology, Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ³Division of Rheumatology, Cincinnati Children’s Hospital Medical Center and Department of Pediatrics, University of Cincinnati, Cincinnati, OH, Cincinnati, OH, ⁴Division of Biostatistics and Epidemology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, ⁷Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁸Cincinnati Children's Hospital, Cincinnati, ⁹UCSF/Proctor Foundation, San Francisco, IL, ¹⁰Cole Eye Institute, Cleveland Clinic;, Cleveland, OH, ¹¹Truhlsen Eye Institute, University of Nebraska Medical Center., Nebraska, NE, ¹²Cincinnati Children's Hospital, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis-associated uveitis (JIA-U) is an ocular disease that can be unilateral or bilateral. Measurement of ocular inflammation is performed by ophthalmic examination…
Abstract Number: 0354 • ACR Convergence 2024
Factors Associated with Health Information Technology Use Among United States Adults with Arthritis from 2012-2017: Analysis of the National Health Interview Survey
Sarah Lieber¹, Jerad Moxley², M. Carrington Reid² and Sara Czaja², ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Health information technology (HIT) use has been associated with numerous benefits including improvements in quality of care and patient safety. Factors associated with HIT…
Abstract Number: 0369 • ACR Convergence 2024
Can Treatment Expectations or Treatment Itself in Patients with Arthralgia Suspicious for Progression to Rheumatoid Arthritis Improve Illness Perceptions?
Simonetta van Griethuysen¹, Quirine Dumoulin² and Annette van der Helm-van Mil³, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Negative Illness perceptions (IPs) are associated with poorer disease outcomes in rheumatoid arthritis (RA). Unfortunately, IPs are generally fixed in established RA. We hypothesized…
Abstract Number: 0327 • ACR Convergence 2024
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
Samuel Govea-Peláez¹, Beatriz Alcalá-Carmona², Jennifer Balderas Miranda³, Yatzil Reyna-Juárez², María José Ostos-prado², Nancy R Mejía-Domínguez², Guillermo Juarez-Vega⁴, Jiram Torres Ruiz⁵ and Diana Gomez-martin⁶, ¹INCMNSZ, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Distrito Federal, Mexico, ³Universidad Nacional Autónoma de México, Ciudad de México, Mexico, ⁴Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, ⁵INCMNSZ, Mexico, Federal District, Mexico, ⁶INCMNSZ, Mexico City, Federal District, Mexico
Background/Purpose: Patients with idiopathic inflammatory myopathies (IIM) have reported chronic pain despite having normal serum muscular enzymes, physician global assessment (PhGA) and MMT8 scores, thus…
Abstract Number: 0408 • ACR Convergence 2024
Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study
Michael Matt¹, Mariana Correia Marques², Sabrina Fuehner³, Lexi Auld¹, George Tomlinson⁴, Michael Ombrello⁵, Yukiko Kimura⁶, Christoph Kessel⁷ and grant schulert¹, and the CARRA FROST Investigators, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²National Institutes of Health, Bethesda, MD, ³Universitaetsklinikum Muenster, Muenster, Germany, ⁴University of Toronto, Toronto, ON, Canada, ⁵National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ⁶Hackensack Meridian School of Medicine, New York, NY, ⁷University Hospital Muenster, Muenster, Germany
Background/Purpose: IL-1 inhibitors are both widely used and highly effective as first-line therapy for children with systemic juvenile idiopathic arthritis (sJIA); however, the mechanisms underlying…
Abstract Number: 0277 • ACR Convergence 2024
Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation
Jennifer Lee¹ and Ah Young Choi², ¹seoul st mary's hospital, Seoul, South Korea, ²The Cactholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Mesenchymal stem cells (MSCs) have anti-inflammatory properties and have been implicated in several inflammatory diseases. Acute gout is initiated by IL-1β produced by monosodium…
Abstract Number: 0397 • ACR Convergence 2024
Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022
Priyanka Yalamanchili¹, Lydia Lee², Greta Bushnell³, Melissa Mannion⁴, Chintan Dave⁵ and Daniel B. Horton⁶, ¹Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research, Morris Plains, NJ, ²Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, Piscataway, NJ, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health, New Brunswick, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ, ⁶Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disorder. An increasing array of disease-modifying antirheumatic drugs (DMARDs) have become available to treat…
Abstract Number: 0389 • ACR Convergence 2024
Histopathological Features of Liver Tissue Biopsies in SJIA Patients with and Without Clinical Macrophage Activation Syndrome
Esraa Eloseily¹, Lara Berklite², Jennifer Picarsic¹, grant schulert¹, Rachel Sheridan¹ and Alexei Grom¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnti, OH
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) can present with or without Macrophage Activation Syndrome (MAS), a severe, potentially life-threatening complication. Liver tissue injury is commonly…
Abstract Number: 0329 • ACR Convergence 2024
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
Raisa Silva¹, Manuel Carpio Tumba², Sneha Gupta³, Latika Gupta⁴, Pedro M Machado⁵, Julie Paik⁶, Diana Louden⁷, Lesley Ann Saketkoo⁸, Sebastian E. Sattui² and Didem Saygin⁹, ¹Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, ²University of Pittsburgh, Pittsburgh, PA, ³University of Pittsburgh Medical Center McKeesport, Pittsburgh, PA, ⁴Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom, ⁵Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ⁶Johns Hopkins University, Baltimore, MD, ⁷University of Washington Libraries, Seattle, WA, ⁸New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, Louisiana State University and Tulane University Medical Schools, New Orleans, LA, ⁹Rush University Medical Center, Chicago, IL
Background/Purpose: The growing number of randomized clinical trials (RCTs) in idiopathic inflammatory myopathies (IIMs) points to a promising future for therapeutics in IIM. Adequate representation…
Abstract Number: 0341 • ACR Convergence 2024
Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease
Kaito Aoki¹, Keigo Shimura¹, Toshiki Ohisa¹, Akira Ishii¹, Mai Sugiyama², Yuichiro Ota¹, Ayumi Nishikawa³, Noriko Sasaki³, Chiho Yamada¹ and Shinji Sato², ¹Tokai University School of Medicine, Isehara, Japan, ²Tokai University, Isehara, Japan, ³Tokai University Hachioji Hospital, Hachioji, Japan
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are chronic inflammatory disorders that affect muscle, skin and lung to varying degrees. Interstitial lung disease (ILD) is a major…
Abstract Number: 0304 • ACR Convergence 2024
Severe Infection in COVID-19 Vaccinated Patients with Systemic Autoimmune Rheumatic Diseases on B Cell Targeted Therapies: Association with Neutrophil-lymphocyte Ratio
doryan Garcia Olivas¹, Judith Hernández Sánchez¹, luis Bausá Gimeno¹, Javier Nóvoa Medina¹, Sergio Machín¹, Maria Ángeles Acosta-Mérida¹, Diana Botello-Corzo¹, daniel Batista Perdomo¹, José Ángel Hernández Beriain² and Beatriz Tejera Segura¹, ¹Rheumatology Department. Hospital Universitario Insular de Gran Canaria, las Palmas, Spain, ²Rheumatology Department. Hospital Universitario Insular de Gran Canaria, Las Palmas de Gran C, Spain
Background/Purpose: Patients with systemic autoimmune rheumatic diseases (SARDs) are at higher risk of general infection due to the presence of comorbidities, underlying disease activity, and…
Abstract Number: 0294 • ACR Convergence 2024
Obesity and Risk of Autoimmune Diseases: Insights from the National Inpatient Sample
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Obesity has been implicated as a risk factor in developing various cardiovascular, respiratory, and other health complications. However, the link between obesity and autoimmune…
Abstract Number: 0403 • ACR Convergence 2024
Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process
Melissa Oliver¹, susan Thornhill², Beverley Shea³, Jonathan Akikusa², Christian Hedrich⁴, Philip Mease⁵ and Yongdong (Dan) Zhao⁶, and OMERACT CNO & SAPHO Working Group, ¹Indiana University, Indianapolis, IN, ²Royal Children's Hospital, Parkville, Victoria, Australia, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴University of Liverpool, Liverpool, United Kingdom, ⁵Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, ⁶University of Washington, Redmond, WA
Background/Purpose: Disease outcome measures for chronic nonbacterial osteomyelitis (CNO) & Synovitis, Acne, Pustulosis, Hyperostosis and Osteitis (SAPHO) have been proposed and reported but have lacked…
Abstract Number: 0395 • ACR Convergence 2024
Assessment of Enthesitis by Pediatric Rheumatology Providers
Erin Treemarcki¹, Shirley Tse², Marisa Klein-Gitelman³, Adam Mayer⁴, Hemalatha Srinivasalu⁵, Heather Walters⁶ and Melissa Oliver⁷, and the CARRA Juvenile Spondyloarthritis Workgroup and the CARRA investigators, ¹University of Utah, Salt Lake City, UT, ²SickKids, Toronto, ON, Canada, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Children's National Hospital, Washington, DC, ⁶Northwell Health, New Hyde Park, NY, ⁷Indiana University, Indianapolis, IN
Background/Purpose: Enthesitis is a characteristic feature of enthesitis related arthritis (ERA) but can be found in other juvenile idiopathic arthritis (JIA) subtypes. It occurs with…
Abstract Number: 0393 • ACR Convergence 2024
Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA
Marianne Kerski¹, Smriti Mohan¹, Cynthia Vizcaya², Reema Sutariya³, Weibin Bao³ and Matthew Stoll⁴, ¹University of Michigan, Ann Arbor, MI, ²Novartis Pharmaceutical Corporation, East Hanover, NJ, ³Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Early recognition and treatment of temporomandibular joint (TMJ) arthritis in children with juvenile idiopathic arthritis (JIA) is of high importance given its impact on…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].